Clinical trial · no report yet · Phase 1/Phase 2
LIBRETTO-121
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
- NCT03899792 ↗
- Active not recruiting
- Eli Lilly and Company
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
- Phase
- Phase 1/Phase 2
- Status
- Active not recruiting
- Conditions
- Medullary Thyroid Cancer; Infantile Myofibromatosis; Infantile Fibrosarcoma; Papillary Thyroid Cancer; Soft Tissue Sarcoma
- Interventions
- Selpercatinib
- Arms
- Cohort 1: Medullary Thyroid Cancer (MTC) Group · Experimental
- Cohort 2: Papillary Thyroid Cancer (PTC) Group · Experimental
- Cohort 3: Other Cancer Group · Experimental
- Enrollment
- 36
- Primary outcomes
- Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
- Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study
- Sponsor
- Eli Lilly and Company with Loxo Oncology, Inc.
- Start
- Jun 13, 2019
- Primary completion
- Nov 8, 2024
- Results posted
- Yes
- Registry record
- NCT03899792 · updated Jan 6, 2026